Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | Zendy

Ian D. Davis | Zendy; Andrew Martin | Zendy; Martin R. Stockler | Zendy; Stephen Begbie | Zendy; Kim N. | Zendy; Simon Chowdhury | Zendy; Xanthi Coskinas | Zendy; Mark Frydenberg | Zendy; Wendy Hague | Zendy; Lisa G. Horvath | Zendy; Anthony M. Joshua | Zendy; Nicola Jane Lawrence | Zendy; Gavin Marx | Zendy; John McCaffrey | Zendy; Ray McDermott | Zendy; Margaret McJannett | Zendy; Scott North | Zendy; Francis Parnis | Zendy; Wendy R. Parulekar | Zendy; David Pook | Zendy; M. Neil Reaume | Zendy; Shahneen Sandhu | Zendy; Alvin Tan | Zendy; Thean Hsiang Tan | Zendy; Alastair Thomson | Zendy; Emily Tu | Zendy; Francisco Vera-Badillo | Zendy; Scott Williams | Zendy; Sonia Yip | Zendy; Alison Y. Zhang | Zendy; Robert Zielinski | Zendy; Christopher J. Sweeney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Author(s) -

Ian D. Davis,

Andrew Martin,

Martin R. Stockler,

Stephen Begbie,

Kim N.,

Simon Chowdhury,

Xanthi Coskinas,

Mark Frydenberg,

Wendy Hague,

Lisa G. Horvath,

Anthony M. Joshua,

Nicola Jane Lawrence,

Gavin Marx,

John McCaffrey,

Ray McDermott,

Margaret McJannett,

Scott North,

Francis Parnis,

Wendy R. Parulekar,

David Pook,

M. Neil Reaume,

Shahneen Sandhu,

Alvin Tan,

Thean Hsiang Tan,

Alastair Thomson,

Emily Tu,

Francisco Vera-Badillo,

Scott Williams,

Sonia Yip,

Alison Y. Zhang,

Robert Zielinski,

Christopher J. Sweeney

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903835

Subject(s) - enzalutamide , medicine , hazard ratio , prostate cancer , clinical endpoint , oncology , docetaxel , adverse effect , progression free survival , discontinuation , androgen deprivation therapy , antiandrogen , confidence interval , randomized controlled trial , cancer , androgen receptor , overall survival

Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research